I would be careful interpreting the results of this study
As you know Breast Cancer is not one disease. her2+ breast cancer has different genes turned on/off, behaves differently, responds to different treatments etc.
It will take a while to determine what ER+her2+ patients should do ie, only take AIs when on herceptin, switch to fulvestrant once herceptin ends, OK to stay on AIs once herceptin stops, should be treated from day one with herceptin, should be treated with a new nano-formulated fulvestrant like drug (just saw article today--only done in mice so far!), how long to do it ie, whether recurrence incidence for her2+ER+ persists for more years than for her2+ER-. Lots of questions to be answered--keeping up on the literature and supporting breast cancer research is in all our interests!
|
